STOK STOKE THERAPEUTICS INC Expansion Plans 8-K Filing 2025 - Phase 3 Study Stoke Therapeutics announced plans for a Phase 3 study of zorevunersen, a potential treatment for Dravet syndrome, with a target start date in mid-2025 and data expected by the end of 2027.Get access to all SEC 8-K filings of the STOKE THERAPEUTICS INC